After applying for Class I medical device registration with ANVISA in Brazil, manufacturers and their representatives must continue to comply with various regulatory requirements and obligations to ensure ongoing compliance. These include post-registration regulations, quality control, and reporting obligations. Here is a summary of the key regulations and requirements that must be followed after applying for Class I medical device registration:

1. Compliance with ANVISA Regulations

Once the application is submitted, and potentially approved, manufacturers must comply with the following key regulations:

RDC 185/2001 (Medical Device Registration)

• RDC 185/2001 is the main regulation for medical device registration in Brazil and outlines the procedures for registration, market surveillance, and control. After registration, manufacturers must ensure that their devices are traceable and can be monitored for safety and performance throughout their life cycle.

RDC 16/2013 (Classification and Risk-Based System)

• Class I devices are classified as low-risk products. This regulation outlines the classification process, which involves assessing the device’s intended use and level of risk.
• Post-registration obligations for manufacturers include ensuring that the product continues to meet safety requirements and that any changes to the device or its classification are updated with ANVISA.

RDC 67/2009 (Labeling Requirements)

• Labeling for medical devices must comply with the requirements established in RDC 67/2009, which includes the obligation to maintain clear and accurate labeling information in Portuguese. The labeling must include:

  • Manufacturer details.
  • Intended use.
  • Warnings and precautions.
  • Batch/lot number and expiration date (if applicable).
  • Storage and handling instructions.

  The Portuguese language requirement is mandatory for all documents and labeling submitted or used within Brazil.

2. Post-Market Surveillance (PMS) and Vigilance

RDC 55/2010 (Post-Market Surveillance)

• Manufacturers must establish and maintain an effective Post-Market Surveillance (PMS) system, as outlined by RDC 55/2010. This regulation mandates that manufacturers continue to monitor the safety and performance of the medical device after it reaches the market.
• This includes:
  • Reporting adverse events (e.g., device malfunctions or injuries).
  • Notifying ANVISA of recalls or any corrective actions that need to be taken.
  • Submitting regular updates on any issues identified through user complaints or clinical data.
  Manufacturers are required to have a system in place to record and investigate any complaints or incidents, as well as ensure the traceability of the device.

RDC 327/2019 (Vigilance for Market Monitoring)

• According to RDC 327/2019, manufacturers must also report any adverse events to ANVISA in line with Vigilance Guidelines.
  • Vigilance refers to monitoring the safety of devices throughout their lifecycle. Any incidents or malfunctions must be investigated and reported to ANVISA in a timely manner, particularly if they pose a risk to public health.
  • Periodic post-market reports may be required by ANVISA to evaluate ongoing safety and performance.

3. Quality Management System (QMS) Compliance

ISO 13485:2016 (Quality Management System)

• If you are a foreign manufacturer or even a local manufacturer, ISO 13485 certification for Quality Management Systems is recommended (and may be required in some cases).
• Ensuring compliance with a QMS means having documented procedures for product design, testing, manufacturing, and quality assurance. The QMS must be maintained to ensure ongoing product safety and performance.
• ANVISA audits may be conducted to verify compliance with GMP (Good Manufacturing Practices), and manufacturers should be prepared for inspections.

4. Good Manufacturing Practices (GMP)

• Manufacturers (especially foreign manufacturers) must maintain compliance with Good Manufacturing Practices (GMP). This may include:
  • Ensuring the manufacturing facility meets GMP standards.
  • Providing documentation demonstrating ongoing adherence to GMP, such as ISO 13485 certification.
  • For local representatives, it is crucial to ensure that all imported products comply with GMP standards before distribution in Brazil.

5. Change Management and Registration Amendments

• If there are any changes to the device (e.g., design, materials, intended use) or the manufacturing process, manufacturers must inform ANVISA and may need to submit an amendment or update to the original registration.
  • Labeling updates (if there are any changes in instructions or warnings) must be submitted to ANVISA for approval.
  • Change requests should be filed if there are updates to the manufacturing process or if a new production site is used.

6. Device Traceability

• Manufacturers, distributors, and importers are required to implement systems for device traceability. This is crucial for:
  • Tracking medical devices from manufacturing to patient use.
  • Ensuring that lot numbers and serial numbers can be traced in case of recalls, malfunctions, or adverse events.
  • Recordkeeping: Maintain records of all devices sold, including batch numbers, lot numbers, and distribution chains, for regulatory and safety purposes.

7. Regulatory Fees and Renewals

• While Class I devices do not generally require annual renewal of their registration, manufacturers should stay aware of any regulatory changes or updated fees from ANVISA.
  • Annual fees might be applicable for annual establishment registration (in the case of manufacturers or importers) or for maintaining the product registration in certain circumstances.
  • Keep in mind that any amendments to the registration may require payment of additional fees.

8. Local Distribution and Importation Compliance

• For imported devices, the importer must ensure that the product is accompanied by the ANVISA registration certificate at customs.
  • Brazilian Customs (Receita Federal) will require proof of ANVISA registration before allowing the device to enter the country.
  • Importers are responsible for keeping ANVISA-compliant records and ensuring that only registered devices are imported.

9. Market Inspections

• ANVISA may conduct market inspections or audits to ensure ongoing compliance with regulatory requirements.
  • Inspections can focus on the manufacturing site, storage facilities, or the local distributor’s operations.
  • Manufacturers should be prepared for possible ANVISA inspections and audits to verify compliance with both the registration and post-market requirements.

10. Ongoing Updates to Regulatory Requirements

• ANVISA may update its regulations or guidance for medical devices over time. Manufacturers and importers must:
  • Stay informed about changes to ANVISA regulations through updates, notifications, or publications.
  • Review product documentation and ensure compliance with any new requirements that may apply.

Summary of Key Post-Registration Obligations:

1. Post-Market Surveillance and adverse event reporting (RDC 55/2010).
2. Compliance with RDC 67/2009 for accurate labeling.
3. Maintain a Quality Management System (QMS), potentially including ISO 13485 certification.
4. Ensure ongoing compliance with Good Manufacturing Practices (GMP).
5. Report and seek approval for any changes to the device or manufacturing process.
6. Implement traceability systems for product safety and recall management.
7. Keep track of any regulatory fees, potential inspections, or registration amendments.
8. Comply with importation and distribution regulations.
9. Stay updated with any new regulatory updates or changes from ANVISA.

By following these post-registration requirements, you can ensure your Class I medical device remains compliant with ANVISA regulations in Brazil and is safely marketed to the public.

Contact Us：

Whatsapp or Wechat：+86 15816864648；email address：hito.lin@grzan.cn